Consistent with this notion, it has been shown recently that the CD47/SIRPA blockade therapy with anti-CD47 antibody in xenograft models of high-risk neuroblastoma requires an additional opsonizing antibody against neuroblastoma, such as anti-GD2 antibody, to be efficacious [42]. Here, SIRPA is linked to neuroblastoma.